Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 117

Similar articles for PubMed (Select 23570281)

1.

ER+ /PR+ /TFF3+ /IMP3- immunoprofile distinguishes endometrioid from serous and clear cell carcinomas of the endometrium: a study of 401 cases.

Mhawech-Fauceglia P, Yan L, Liu S, Pejovic T.

Histopathology. 2013 Jun;62(7):976-85. doi: 10.1111/his.12096. Epub 2013 Apr 9.

PMID:
23570281
2.

IMP3 distinguishes uterine serous carcinoma from endometrial endometrioid adenocarcinoma.

Mhawech-Fauceglia P, Herrmann FR, Rai H, Tchabo N, Lele S, Izevbaye I, Odunsi K, Cheney RT.

Am J Clin Pathol. 2010 Jun;133(6):899-908. doi: 10.1309/AJCPQDQXJ4FNRFQB.

3.

Immunohistochemical characterization of prototypical endometrial clear cell carcinoma--diagnostic utility of HNF-1β and oestrogen receptor.

Hoang LN, Han G, McConechy M, Lau S, Chow C, Gilks CB, Huntsman DG, Köbel M, Lee CH.

Histopathology. 2014 Mar;64(4):585-96. doi: 10.1111/his.12286. Epub 2013 Dec 7.

PMID:
24103020
4.

The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma.

Zheng W, Yi X, Fadare O, Liang SX, Martel M, Schwartz PE, Jiang Z.

Am J Surg Pathol. 2008 Feb;32(2):304-15. doi: 10.1097/PAS.0b013e3181483ff8.

PMID:
18223334
5.

Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases.

Darvishian F, Hummer AJ, Thaler HT, Bhargava R, Linkov I, Asher M, Soslow RA.

Am J Surg Pathol. 2004 Dec;28(12):1568-78.

PMID:
15577675
6.

High-grade endometrial carcinoma: serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes.

Alkushi A, Köbel M, Kalloger SE, Gilks CB.

Int J Gynecol Pathol. 2010 Jul;29(4):343-50. doi: 10.1097/PGP.0b013e3181cd6552.

PMID:
20567148
7.
8.

Expression of a novel oncofetal mRNA-binding protein IMP3 in endometrial carcinomas: diagnostic significance and clinicopathologic correlations.

Li C, Zota V, Woda BA, Rock KL, Fraire AE, Jiang Z, Lu D, Xu B, Dresser K, Lutman CV, Fischer AH.

Mod Pathol. 2007 Dec;20(12):1263-8. Epub 2007 Sep 21.

9.

Trefoil factor family 3 (TFF3) expression and its interaction with estrogen receptor (ER) in endometrial adenocarcinoma.

Mhawech-Fauceglia P, Wang D, Samrao D, Liu S, DuPont NC, Pejovic T.

Gynecol Oncol. 2013 Jul;130(1):174-80. doi: 10.1016/j.ygyno.2013.03.030. Epub 2013 Apr 8.

PMID:
23578537
10.

Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.

Sieh W, Köbel M, Longacre TA, Bowtell DD, deFazio A, Goodman MT, Høgdall E, Deen S, Wentzensen N, Moysich KB, Brenton JD, Clarke BA, Menon U, Gilks CB, Kim A, Madore J, Fereday S, George J, Galletta L, Lurie G, Wilkens LR, Carney ME, Thompson PJ, Matsuno RK, Kjær SK, Jensen A, Høgdall C, Kalli KR, Fridley BL, Keeney GL, Vierkant RA, Cunningham JM, Brinton LA, Yang HP, Sherman ME, García-Closas M, Lissowska J, Odunsi K, Morrison C, Lele S, Bshara W, Sucheston L, Jimenez-Linan M, Driver K, Alsop J, Mack M, McGuire V, Rothstein JH, Rosen BP, Bernardini MQ, Mackay H, Oza A, Wozniak EL, Benjamin E, Gentry-Maharaj A, Gayther SA, Tinker AV, Prentice LM, Chow C, Anglesio MS, Johnatty SE, Chenevix-Trench G, Whittemore AS, Pharoah PD, Goode EL, Huntsman DG, Ramus SJ.

Lancet Oncol. 2013 Aug;14(9):853-62. doi: 10.1016/S1470-2045(13)70253-5. Epub 2013 Jul 9.

11.

Utility of α-methylacyl-coenzyme-A racemase (p504s) immunohistochemistry in distinguishing endometrial clear cell carcinomas from serous and endometrioid carcinomas.

Fadare O, Parkash V, Gwin K, Hanley KZ, Jarboe EA, Liang SX, Quick CM, Zheng W, Rawish KR, Hecht JL, Desouki MM.

Hum Pathol. 2013 Dec;44(12):2814-21. doi: 10.1016/j.humpath.2013.07.033. Epub 2013 Oct 10.

12.

Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis.

Reid-Nicholson M, Iyengar P, Hummer AJ, Linkov I, Asher M, Soslow RA.

Mod Pathol. 2006 Aug;19(8):1091-100. Epub 2006 Apr 28.

13.
14.

Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of endometrium.

Halperin R, Zehavi S, Habler L, Hadas E, Bukovsky I, Schneider D.

Eur J Gynaecol Oncol. 2001;22(2):122-6.

PMID:
11446475
15.
16.

Histologic and immunohistochemical analyses of endometrial carcinomas: experiences from endometrial biopsies in 358 consultation cases.

Wei JJ, Paintal A, Keh P.

Arch Pathol Lab Med. 2013 Nov;137(11):1574-83. doi: 10.5858/arpa.2012-0445-OA.

PMID:
24168495
17.

Absence of estrogen receptor-alpha expression in human ovarian clear cell adenocarcinoma compared with ovarian serous, endometrioid, and mucinous adenocarcinoma.

Fujimura M, Hidaka T, Kataoka K, Yamakawa Y, Akada S, Teranishi A, Saito S.

Am J Surg Pathol. 2001 May;25(5):667-72.

PMID:
11342781
18.

DJ-1 in endometrial cancer: a possible biomarker to improve differential diagnosis between subtypes.

Morelli M, Scumaci D, Di Cello A, Venturella R, Donato G, Faniello MC, Quaresima B, Cuda G, Zullo F, Costanzo F.

Int J Gynecol Cancer. 2014 May;24(4):649-58. doi: 10.1097/IGC.0000000000000102.

PMID:
24614826
19.

Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.

Høgdall EV, Christensen L, Høgdall CK, Blaakaer J, Gayther S, Jacobs IJ, Christensen IJ, Kjaer SK.

Oncol Rep. 2007 Nov;18(5):1051-9.

PMID:
17914554
20.

[The value of progesterone and estrogen receptors expression in tissue microarray method in prognosis of patients with endometrioid endometrial cancer].

Gottwald L, Kubiak R, Pasz-Walczak G, Sek P, Piekarski J, Szwalski J, Spych M, Chałubińska-Fendler J, Suzin J, Tyliński W, Jeziorski A.

Ginekol Pol. 2013 Feb;84(2):95-101. Polish.

PMID:
23668054
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk